Fiche publication
Date publication
janvier 2015
Journal
Nanomedicine (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROUX Stéphane
,
Dr ROUX Stéphan
Tous les auteurs :
Lux F, Sancey L, Bianchi A, Crémillieux Y, Roux S, Tillement O
Lien Pubmed
Résumé
A rapid development of gadolinium-based nanoparticles is observed due to their attractive properties as MRI-positive contrast agents. Indeed, they display high relaxivity, adapted biodistribution and passive uptake in the tumor thanks to enhanced permeability and retention effect. In addition to these imaging properties, it has been recently shown that they can act as effective radiosensitizers under different types of irradiation (radiotherapy, neutron therapy or hadron therapy). These new therapeutic modalities pave the way to therapy guided by imaging and to personalized medicine.
Mots clés
MRI, gadolinium, multimodality, nanoparticles, oncology, radiotherapy, theranostic
Référence
Nanomedicine (Lond). 2015 ;10(11):1801-15
